We have shown recently that CTLs generated to glycopeptide antigens were protective against MUC1-expressing mouse tumors in MUC1 transgenic mice and that both glycosylated 9-mer peptides as well as non-glycosylated 9-mer peptides could induce both CD4+ and CD8+ T cells that produced IFNγ and recognized various glycosylated MUC1 peptides and tumor-associated MUC1 as well as controlled tumor growth in MUC1 transgenic mice with repetitive vaccination [34]. This evidence concerns the gene CD8A and neoplasm.